On February 1, 2021 IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, reported its participation at the following upcoming investor relations events (Press release, Ideaya Biosciences, FEB 1, 2021, View Source [SID1234574475]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Relations Events

Guggenheim Healthcare Talks 2021 Oncology Day (Virtual)
Fireside Chat with Analyst Michael Schmidt
Friday, February 12th, 2021 at 12:00 pm ET

LifeSci Partners Precision Oncology Event (Virtual)
Company Presentation
Wednesday, February 17th, 2021, at 2:00pm ET
A live audio webcast of each presentation will be available by visiting the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source A replay of the webcasts will be available for 30 days following the live event.

On February 1, 2021 Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported new data demonstrating regression of an animal model of glioma using exosomes isolated from the Company’s cellular immunotherapy product StemVacs (Press release, Therapeutics Solutions International, FEB 1, 2021, View Source [SID1234574474]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Exosomes are cell derived nanoparticles which have been demonstrated to transmit biological information between cells. Dr. Thomas Ichim, Board Member of the Company, published 16 years ago that exosomes from cancer are capable of suppressing immunity1. Today the Company reported opposite findings: in some situations, immune cell exosomes can suppress cancer.

"The current findings demonstrate that StemVacs derived exosomes can directly stimulate natural killer cells, which in turn, suppress glioma growth" said Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor of the patent. "Exosomes in some cases possess advantages to administration of cells in that they are more stable than cells and are capable of superior biodistribution due to their small size."

"As a clinical stage cancer immunotherapy company, experimental validation of our intellectual property is extremely important for accomplishing our goals of entering into licensing and/or co-development relationships with Large Pharma" stated Famela Ramos Vice President of Business Development. "The fact that companies such as Fate Therapeutics and Nantkwest are attracting valuations in the billions of dollars, supports our belief that the field of natural killer therapeutics is highly perceived by the industry".

"We are in the process of developing responses to our last interaction with the FDA regarding StemVacs cell therapy" said Timothy Dixon, President and CEO of the Company. "By leveraging our scientific colleagues and finding that StemVacs exosomes are effective in glioma, we are evaluating the possibility of applying for another Investigational New Drug application using exosomes."

On February 1, 2021 Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, reported that the Company will be presenting at the following upcoming virtual investor conference (Press release, Inhibrx, FEB 1, 2021, View Source [SID1234574473]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks: 2021 Oncology Days; Friday, February 12th, at 2 p.m. Pacific Time
The investor conference presentation will be webcast live and may be accessed through a link on the investors section of Inhibrx’s website at View Source The webcast will be available for 60 days following the event.

On February 1, 2021 OncoNano Medicine, Inc. reported the appointment of Martin Driscoll as Chief Executive Officer and a member of the company’s Board of Directors (Press release, OncoNano Medicine, FEB 1, 2021, View Source [SID1234574472]). An accomplished industry veteran with multiple decades of biopharmaceutical development and commercialization experience, Mr. Driscoll most recently served as President and Chief Executive Officer of Spring Bank Pharmaceuticals. Mr. Driscoll succeeds co-founder and CEO Ravi Srinivasan, Ph.D., who has stepped down in a planned transition to pursue other interests.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to welcome Marty to our team. Marty’s extensive experience and proven track record at the helm of several successful biopharmaceutical development companies will undoubtedly provide OncoNano with the leadership to advance our business and translate our novel discoveries into important new interventions and treatments for cancer patients," said Al Guillem, Ph.D., Chairman of OncoNano. "Marty joins OncoNano at an important time as we progress our lead program into the pivotal trial stage and advance our first oncology therapeutic, ONM-501, towards the first human studies for this novel immuno-modulator." Dr. Guillem continued, "On behalf of the OncoNano board of directors, I want to thank Ravi for his many contributions to the growth of our company and wish him great success in his future endeavors."

"I’m joining OncoNano at an exciting point in the evolution of the company and I look forward to building on the strong foundation established by Ravi and the OncoNano team as we advance the clinical development of our impressive portfolio of differentiated programs," said Mr. Driscoll. "I was attracted to this opportunity to lead OncoNano by the exciting potential for the company’s innovative core technology that exploits the universal pH biomarker of solid tumors to enhance real-time surgical imaging and enable more efficient and effective delivery of cancer treatments."

Mr. Driscoll brings a proven record in leading privately-held and publicly-traded biopharmaceutical development and commercial-stage companies. He has been involved with or led the commercialization of several important therapies, the direct negotiation of numerous licensing and M&A transactions, multiple private and public capital fundraising efforts and the successful submission of major global product regulatory filings. Mr. Driscoll has also served as a director on the boards of eight biopharmaceutical and diagnostic companies during his career.

On February 1, 2021 Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, reported that Gilead Sciences is increasing its ownership in Arcus to 19.5%, from approximately 13%, by purchasing 5,650,000 additional shares of Arcus’s common stock at a per share purchase price of $39.00 (Press release, Arcus Biosciences, FEB 1, 2021, View Source [SID1234574471]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Gilead’s additional investment in Arcus demonstrates the strength of our relationship, a recognition of the depth of our pipeline and our shared commitment to bringing innovative, transformative therapies to cancer patients as quickly as possible," said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. "The proceeds from this financing will support and enable the acceleration of our development plans for our four clinical-stage molecules, including AB680, our small molecule CD73 inhibitor, for which we recently presented encouraging data in first-line metastatic pancreatic cancer. We appreciate Gilead’s continued confidence in Arcus and our ability to execute. We look forward to providing a multitude of data readouts across our entire portfolio of clinical molecules, including the ARC-7 study interim analysis for domvanalimab expected in the second quarter, throughout what we expect will be a transformational year for the company."

The Arcus-Gilead partnership, which closed in July 2020, includes an Option, License and Collaboration Agreement, a Common Stock Purchase Agreement, and an Investor Rights Agreement. Collectively, this transaction established a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies, provided for an initial equity investment and upfront payment to Arcus totaling $375 million, and gave Gilead the right, but not the obligation, to make additional equity investments in Arcus by purchasing additional shares of Arcus’s common stock. Arcus and Gilead entered into an amended and restated Common Stock Purchase Agreement to provide for this purchase of 5,650,000 additional shares of Arcus’s common stock. No other agreements or terms were amended. Following this investment, Arcus expects its cash and investments to fund its operations through at least 2023.